Oral anticoagulation after myocardial infarction

Herz

Volumn 33, Issue 1, 2008, Pages 38-43

  Hurlen, Mette ^a   Arnesen, Harald ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Aspirin; Myocardial Infarction; Oral anticoagulants

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; COUMARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; PATIENT COMPLIANCE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM;

EID: 39449136532     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-008-3074-8     Document Type: Review

References (29)

1. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
3. Davies MJ, Woolf N, Robertson WB. Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi. Br Heart J 1976;38:659-64.
4. Ridolfi RL, Hutchins GM. The relationship between coronary artery lesions and myocardial infarcts: ulceration of atherosclerotic plaques precipitating coronary thrombosis. Am Heart J 1977;93:468-86.
5. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation1985;71:699-708.
6. Libby P, Mach F, Schönbeck U, et al. Regulation of the thrombotic potential of atheroma. Thromb Haemost 1999;82:736-41.
7. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Circulation 1996;94:3090-7.
8. Hirsh J, Poller L. The International Normalized Ratio. A guide to understanding and correcting its problems. Arch Intern Med 1994;154:282-8.
9. Van Es RF, Junker JCJ, Verheugt FWA, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomized controlled trial. Lancet 2002;360:109-13.
10. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. The WARIS-II trial. N Engl J Med 2002;347:969-74.
11. International Anticoagulation Review Group. Collaborative analysis of long-term anticoagulant administration after myocardial infarction. Lancet 1970;1:203-9.
12. Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-94.
13. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-52.
14. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
15. Antiplatelet Trialist Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - 1. BMJ 1994;308:81-106.
16. Hurlen M, Erikssen J, Smith P, et al. Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3166 outpatients. J Intern Med 1994;236:299-304.
17. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389-96.
18. Fiore LD, Ezecowitz MD, Brophy MT, et al. Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction. Primary results of the CHAMP study. Circulation 2002;105:557-63.
19. Hurlen M, Eikvar L, Seljeflot I, et al. Occult bleeding in three different antithrombotic regimens after myocardial infarction. A WARIS-II subgroup analysis. Thromb Res 2006;118:433-8.
20. Brouwer MA, van den Berg PJPC, Aengevaeren WRM, et al. Aspirin plus coumadin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction. Circulation 2002;106:659-65.
21. Herlitz J, Holm J, Peterson M, et al., LoWASA Study Group. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction. The LoWASA study. Eur Heart J 2004;25:232-9.
22. Chalmers TC, Matta RJ, Smith H, et al. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297:1091-6.
23. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-67.
24. Anand S, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003;41:Suppl:62S-9S.
25. Andreotti F, Testa L, Guiseppe GL, et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25307 patients. Eur Heart J 2006;27:519-26.
26. Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: a meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241-50.
27. Loeliger EA. Oral anticoagulation in patients surviving myocardial infarction. A new approach to old data. Eur J Clin Pharmacol 1984;26:137-9.
28. The CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
29. Wallentin L, Wilcox R, Weaver WD, et al., ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet 2003;362:789-97.